Colony NorthStar, Inc. (CLNS) retreated with the stock falling -0.28% or $-0.04 to close at $14.35 on light trading volume of 2.78M compared its three months average trading volume of 3.93M. The Los Angeles California 90071 based company has been trending up for the last 52 weeks, with the shares price now 52.96% up for the period and up by 3.78% so far this year. With price target of $17.83 and a 66.75% rebound from 52-week low, Colony NorthStar, Inc. has plenty of upside potential, making it a hold with a view buy.
The firm invests in the real estate markets of North America and Europe. Its investment portfolio is primarily composed of real estate equity; real estate and real estate-related debt; and investment management of company-sponsored private equity funds and vehicles. The firm invests in wide spectrum of commercial real estate property types, including but not limited to, office, industrial, retail, hospitality, education, single-family and multifamily residential assets, and geographies, primarily within North America and Europe. It was formerly known as Colony Financial, Inc. Colony Capital, Inc. was formed on June 23, 2009 and is based in Los Angeles, California.
Olin Corporation (OLN) gained $0.92 to close the day at a new closing price of $30.87, a 3.07% increase in value from its previous closing price that moved the stock 142.28% above its 52 week low of $14.02. A total of 2.78M shares exchanged hands during the day compared with its three month average trading volume of 2.2M. The stock, which fluctuated between $29.8 and $30.91 during the day, currently situated 0.68% above its 52 week high. The stock is up by 17.24% in the past one month and up by 27.75% over the past three months. With a one year target estimate of $29.33 and RSI of 70.51, the stock still has upside potential, making it a sell for now.
Olin Corporation manufactures and distributes chemical products in the United States and internationally. It operates through three segments: Chlor Alkali Products and Vinyls, Epoxy, and Winchester. The Chlor Alkali Products and Vinyls segment offers chlorine and caustic soda, ethylene dichloride and vinyl chloride monomers, methyl chloride, methylene chloride, chloroform, carbon tetrachloride, perchloroethylene, trichloroethylene and vinylidene chloride, hydrochloric acid, hydrogen, bleach products, and potassium hydroxide. The Epoxy segment provides allyl chloride and epichlorohydrin for use in resins and other plastic materials, water purification, and pesticides, as well as for the manufacturers of polymers; liquid epoxy resins used in adhesives, paints and coatings, composites, and flooring; and converted epoxy resins and additives for use in electrical laminates, paints and coatings, wind blades, electronics, and construction. The Winchester segment offers sporting ammunition, law enforcement ammunition, reloading components, small caliber military ammunition and components, and industrial cartridges. The company markets its products through its sales force, as well as directly to various industrial customers, mass merchants, retailers, wholesalers, other distributors, and the U.S. Government and its prime contractors. Olin Corporation was founded in 1892 and is headquartered in Clayton, Missouri.
Amicus Therapeutics, Inc. (FOLD) shares were down in last trading by -1.62% to $6.08. It experienced lighter than average volume on day. The stock decreased in value by almost -0.49% over the past week and grew 12.38% in the past month. It is currently trading 10.32% above its 50 day moving average and -7.63% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -38.15% decrease in value from its one year high of $9.83. The RSI indicator value of 62.38, lead us to believe that it is a hold for now.
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has completed Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; ATB200 that is in Phase II studies to treat pompe disease; AT2221, which is in Phase II studies for the treatment of pompe disease; and AT3375 to treat Parkinson’s disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.